Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 30, 2015

View Archived Issues

New data on the efficacy and safety of MM-141 in combination therapy

Urinary proteins linked to adverse outcomes in critically ill patients with AKI

Boehringer Ingelheim divulges ENaC blockers

Roche reports development of mGluR5 antagonists

Spinifex Pharmaceuticals discloses new AT2 antagonists for pain

Rhizen Pharmaceuticals presents PI3Kdelta/gamma inhibitors

Agios Pharmaceuticals discloses new inhibitors of mutant IDH2

Reata enrolls first patient in phase II/III study of RTA-408 in Friedreich's ataxia

Phase II results presented for combination immunotherapy in pancreatic cancer

FDA grants orphan drug designation to tarextumab in pancreatic and small-cell lung cancer

Heat Biologics presents immunological data on HS-410 in non-muscle invasive bladder cancer

Celldex Therapeutics and BMS begin study of varlilumab and Opdivo

Amgen offers overview of fourth quarter 2014

Opexa files registration statement for rights offering

RedHill Biopharma provides update on RHB-104 for Crohn's disease

Taxus Cardium updates on ASPIRE trial of angiogenic gene therapy in angina patients

FDA awards orphan drug designation to Silenseed's siG12D-LODER for pancreatic cancer

AstraZeneca establishes four CRISPR-based research collaborations

FDA clears MediciNova's IND application for MN-001 in NASH

Efficacy study compares Flublok Quadrivalent to a traditional flu vaccine

Exonate presents small-molecules inhibitors of SRPK1 with potential for prostate cancer

SBIR grant supports Crinetics' development of kisspeptin receptor antagonists to treat PCOS

Goodwin Biotechnology and Transporin establish technology collaboration

Lenvatinib increases progression-free survival in phase I/II renal cancer study

Valneva license to Immune Targeting Systems for HBV vaccines with the IC31 adjuvant

FDA awards breakthrough therapy designation to Intercept's obeticholic acid for NASH with fibrosis

FDA approves Bristol-Myers Squibb's Evotaz for HIV-1 infection

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
ASH 2025: Ianalumab data offer break from chronic ITP therapy
BioWorld
Novartis AG’s monoclonal antibody, ianalumab (VAY-736), when added to standard-of-care eltrombopag, extended disease control of primary immune thrombocytopenia...